Search Tag: EMPEROR-Reduced
2021 27 Aug
In a Hot Line Session at the ESC Congress 2021, the results of the EMPEROR-Preserved trial were presented that demonstrated a significant reduction in composite cardiovascular endpoints in patients with heart failure and preserved ejection fraction. This was a pooled analysis of two randomised trials that investigated the beneficial effects of...Read more
2020 29 Aug
In a Hot Line session today at ESC Congress 2020, findings from the EMPEROR-Reduced trial showed that empagiflozin reduces the risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure and a reduced ejection fraction. The findings are published in the New England Journal of Medicine. The clinical trial evaluated...Read more